Klinische Studie

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NCT: NCT06388707 · RECRUITING

NCT-IDNCT06388707

Medizinische Daten: StatusRECRUITING

Startdatum2024-09-13

Abschluss2027-10-31

SponsorNaviFUS Corporation (INDUSTRY)

First posted2024-04-29

Last updated2026-09-15

Kurzzusammenfassung

This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant unilateral or bilateral temporal lobe epilepsy (DR-TLE).

Offizielle Quelle

Auf ClinicalTrials.gov ansehen →

Daten aus der ClinicalTrials.gov-API. Den aktuellsten Status finden Sie im offiziellen Eintrag.